Johnson & Johnson's pharmaceutical unit is on pace to continue generating above-market growth through 2025, with a goal to become a $60bn pharmaceutical company within that timeframe, according to pharmaceuticals worldwide chairman Jennifer Taubert.
No Way To Go But Grow: J&J Outlines Plans To Become A $60bn Pharma In 2025
Management outlined its growth strategy to investors, highlighting plans to file 14 novel drugs with more than $1bn in peak sales by 2025.
